Biotech · Private company
BerGenBio ASA
Track this companyFree. Adds BerGenBio ASA to your Dealase workspace and tells you when its record changes.
Clinical trials80 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- BemcentinibPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BemcentinibPhase 2 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- BemcentinibPhase 2 · Lung Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- BemcentinibPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Bemcentinib; pembrolizumabPhase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 2 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- CytarabinePhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- DecitabinePhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- ErlotinibPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Lung Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 2 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 GenePHASE1_PHASE2 · TERMINATED · started Mar 3, 2023ClinicalTrials.gov NCT05469178 · fetched Nov 12, 2026
- AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing SurgeryEARLY_PHASE1 · TERMINATED · started Jan 2, 2020ClinicalTrials.gov NCT03965494 · fetched Nov 12, 2026
- Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic CancerPHASE1_PHASE2 · TERMINATED · started Jan 3, 2019ClinicalTrials.gov NCT03649321 · fetched Nov 12, 2026
- Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)PHASE2 · COMPLETED · started Oct 2, 2017ClinicalTrials.gov NCT03184571 · fetched Nov 12, 2026
- Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBCPHASE2 · TERMINATED · started Jul 26, 2017ClinicalTrials.gov NCT03184558 · fetched Nov 12, 2026
- Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.PHASE1 · COMPLETED · started Nov 1, 2016ClinicalTrials.gov NCT02922777 · fetched Nov 12, 2026
- A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung CancerPHASE1_PHASE2 · COMPLETED · started Apr 19, 2015ClinicalTrials.gov NCT02424617 · fetched Nov 12, 2026
- A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDSPHASE1_PHASE2 · COMPLETED · started Oct 22, 2014ClinicalTrials.gov NCT02488408 · fetched Nov 12, 2026